Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPME1 | Q9Y570 | 7/20 | 0.60 |
| ▸ | APEH | P13798 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964674 | 0.84 | PPME1 (0.58) | PPME1APEHALDH1A1KMT2A | |
| SCHEMBL3968075 | 0.84 | PPME1 (0.55) | PPME1APEHHTR6MEN1KMT2A | |
| SCHEMBL2457308 | 0.84 | RAPGEF4 (0.58) | PPME1APEHALDH1A1HTTTRIM24 | |
| SCHEMBL3964676 | 0.80 | PPME1 (0.45) | PPME1APEHHTR6TRIM24TRIM33 | |
| SCHEMBL3966831 | 0.80 | MET (0.49) | PPME1HTR6MEN1ALDH1A1KMT2A | |
| SCHEMBL3967048 | 0.80 | PPME1 (0.43) | PPME1APEHHTR6ALDH1A1 | |
| SCHEMBL3969689 | 0.80 | PPME1 (0.64) | PPME1APEHL3MBTL1 | |
| SCHEMBL27577351 | 0.78 | PPME1 (0.44) | PPME1APEHMEN1ALDH1A1LMNA | |
| SCHEMBL3969097 | 0.77 | NOD1 (0.43) | PPME1APEHHTR6MEN1KMT2A | |
| SCHEMBL3968076 | 0.76 | MET (0.47) | PPME1HTR6MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2005530823-A | — | — | 2005-10-13 | — | — | JP | claimed |
| US-20050215553-A1 | Hexahydropyridazine-3-carboxylic acid hydrazide and hydrazone derivatives, combinatorial libraries containing same, pharmaceutical compositions containing same and methods of preparation | AVENTIS PHARMA S.A. (FR) | 2005-09-29 | — | — | US | claimed |
| EP-1515953-A2 | NOVEL HEXAHYDRO-PYRIDAZINE-3-CARBOCYLIC ACID HYDRAZIDE OR HYDRAZONE DERIVATIVES, COMBINATORIAL LIBRARIES CONTAINING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR PREPARING SAME | Aventis Pharma S.A. (FR) | 2005-03-23 | — | — | EP | claimed |
| US-6797745-B1 | Hot melt inks containing styrene or terpene polymers | XEROX CORPORATION | 2004-09-28 | — | — | US | claimed |
| US-6780900-B1 | ALDEHYDE COPOLYMER INK VEHICLE, A NONPOLYMERIC ALDEHYDE VISCOSITY MODIFIER, COLORANT, AN OPTIONAL CONDUCTIVITY ENHANCING AGENT, AN OPTIONAL ANTIOXIDANT, AND AN OPTIONAL UV ABSORBER | XEROX CORPORATION | 2004-08-24 | — | — | US | claimed |
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | claimed |
| EP-1381359-A1 | AURONES AS TELOMERASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-21 | — | — | EP | claimed |
| WO-2003106431-A2 | NOVEL HEXAHYDRO-PYRIDAZINE-3-CARBOCYLIC ACID HYDRAZIDE OR HYDRAZONE DERIVATIVES, COMBINATORIAL LIBRARIES CONTAINING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR PREPARING SAME | AVENTIS PHARMA S.A. (FR) | 2003-12-24 | — | — | WO | claimed |
| WO-2002083123-A1 | AURONES AS TELOMERASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2002-10-24 | — | — | WO | claimed |
| WO-2022063115-A1 | BICYCLIC COMPOUNDS AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2022-03-31 | — | — | WO | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| US-5248782-A | Fluorescent dyes | MOLECULAR PROBES, INC. (US) | 1993-09-28 | — | — | US | disclosed |
| EP-0077024-B1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PRODUCTS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-08-12 | — | — | EP | disclosed |
| US-4585771-A | Antiinflammatory imidazole derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-04-29 | — | — | US | disclosed |
| US-4466976-A | Antiinflammatory and antiallergic imidazole derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-08-21 | — | — | US | disclosed |
| EP-0077024-A2 | Imidazole derivatives, process for their preparation and pharmaceutical products containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | PPME1 332/4885APEH 2736/4885HTR6 3369/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | PPME1 619/4885APEH 2759/4885HTR6 4368/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | PPME1 2260/4885APEH 2019/4885HTR6 4195/4885 |
| US-20050215553-A1 | Hexahydropyridazine-3-carboxylic acid hydrazide and hydrazone derivatives, combinatorial libraries containing same, pharmaceutical compositions containing same and methods of preparation | HK1, ACE, CTSZ | PPME1 471/4885APEH 9/4885HTR6 2633/4885 |
| US-20040132807-A1 | Aurones as telomerase inhibitors | TERT, TERF2, TERF2IP | PPME1 427/4885APEH 3570/4885HTR6 3788/4885 |
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP1, CASP14, CASP4 | PPME1 693/4885APEH 446/4885HTR6 2603/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | PPME1 619/4885APEH 2759/4885HTR6 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.